|
Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Metastatic Testicular Cancer Clinical Trials Resources presented on Clinical Trials Search is not meant to be a substitute for proven health advice, calls or treatment with a real medical. We aren't mDs. Always consult your doctor on Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Metastatic Testicular Cancer conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Metastatic Testicular Cancer Clinical research trials and Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Metastatic Testicular Cancer healthcare trials take place in a lot of of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectiveness of new does drugs. The function of the studies / projects is to figure out specific human medical questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to find cures for all varieties of conditions, like Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Metastatic Testicular Cancer. Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Metastatic Testicular Cancer Clinical Trials and other clinical trials allow volunteers to access health treatment options before they are available to the masses. Many times the subjects receive professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Metastatic Testicular Cancer clinical trial. Human subjects often obtain the finest healthcare possible for their Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Metastatic Testicular Cancer condition. Hazards are a reality, nevertheless, and might include additional or frequent dr. calls, health hazards (potentially life-jeopardizing), and/or the treatment being uneffective. Trials are federally regulated with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Metastatic Testicular Cancer  Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Metastatic Testicular Cancer
Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Metastatic Testicular Cancer
For Condition: Reproductive Cancer,Testicular Cancer
Status: No longer recruiting
Sponsor(s): Medical Research Council ,
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining paclitaxel, ifosfamide, and cisplatin in treating patients who have metastatic testicular cancer that has recurred following treatment.
Details: OBJECTIVES: - Determine the feasibility of combining paclitaxel, ifosfamide, and cisplatin induction in patients with metastatic nonseminomatous germ cell tumor of the testis in first relapse following first line treatment with bleomycin, etoposide, and cisplatin. - Determine the response rates to this regimen in these patients OUTLINE: This is a multicenter study. Patients receive paclitaxel IV over 3 hours and ifosfamide IV and cisplatin IV daily for 5 days. Patients with stable or responding disease repeat treatment every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. PROJECTED ACCRUAL: A minimum of 25 patients will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 16 Years/64 Years
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Metastatic nonseminomatous germ cell tumor of the testis - In first relapse following first line treatment with bleomycin, etoposide, and cisplatin - Biopsy proven germ cell tumor OR - Rising tumor markers (alpha fetoprotein and/or human chorionic gonadotropin) - No brain metastases PATIENT CHARACTERISTICS: Age: - 16 to 64 Performance status: - 0-2 Life expectancy: - Not specified Hematopoietic: - Not specified Hepatic: - Not specified Renal: - Glomerular filtration rate greater than 50 mL/min Other: - No other prior malignancy except curatively treated nonmelanomatous skin cancer or superficial bladder cancer PRIOR CONCURRENT THERAPY: Biologic therapy: - Not specified Chemotherapy: - See Disease Characteristics Endocrine therapy: - Not specified Radiotherapy: - Not specified Surgery: - Not specified Other: - No prior experimental drugs
Total Enrollment:
Location and Contact Information:
Overall Study Official:
MalcolmMason, Study Chair, Velindre Hospital
Velindre Hospital
Cardiff, Wales, CF14 2TL
United Kingdom
Additional Information:
Study ID Numbers: CDR0000067286; MRC-TIP,EU-99012
Study Start Date:
Record last reviewed: May 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00004077
Other Testicular Cancer Studies:
1. Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation
2. Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors
3. Comparison of Antibody Therapies in Treating Patients With Graft- Versus-Host Disease That Does Not Respond to Steroid Therapy
4. Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Metastatic Testicular Cancer
5. BMS-247550 in Treating Patients With Advanced Cisplatin-Refractory Germ Cell Tumors
Related Studies:
Other Testicular Cancer Clinical Trials
Other Wales Clinical Trials
Other Cardiff Clinical Trials
Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Metastatic Testicular Cancer
|
|
|
|
|
|
|
|
